The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular characterization of resected non-metastatic pancreatic cancer (PC) based on KRAS status.
 
Angelo Pirozzi
No Relationships to Disclose
 
Ellen Jaeger
Employment - Tempus AI, Inc
Stock and Other Ownership Interests - Tempus AI, Inc; Tempus AI, Inc
 
Cody Eslinger
No Relationships to Disclose
 
Matina Fragkogianni
Employment - Tempus AI, Inc.
Stock and Other Ownership Interests - Tempus AI, Inc.
 
Unnati Jariwala
Employment - Magnit Global (Daiichi Sankyo contract assignment); Tempus AI
Stock and Other Ownership Interests - Tempus AI
 
Arya Ashok
Employment - Tempus
Stock and Other Ownership Interests - Tempus
Travel, Accommodations, Expenses - Tempus
 
Naohiro Okano
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Celine Hoyek
No Relationships to Disclose
 
Taro Shibuki
No Relationships to Disclose
 
Binbin Zheng-Lin
No Relationships to Disclose
 
Oluseyi Abidoye
No Relationships to Disclose
 
Daniel Ahn
Stock and Other Ownership Interests - Lilly; Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genentech/Roche; Incyte; Incyte; Novartis
Research Funding - AstraZeneca; Bayer
 
Christina Wu
Honoraria - Cancer Treament Centers of America; Medscape
Consulting or Advisory Role - Daiichi Sankyo/Lilly; DoMore Diagnostics; Exelixis; Merck; Natera; Natera; Nova Research Company; Pfizer; Seagen
Research Funding - Abbvie (Inst); DynamiCure Biotechnology (Inst); HUTCHMED; HUTCHMED (Inst); Pfizer; Sirnaomics (Inst); Sumitomo Pharma (Inst)
 
Mohamad Sonbol
Honoraria - Novartis
Consulting or Advisory Role - Bayer (Inst); Boehringer Ingelheim (Inst)
Research Funding - Lilly (Inst); Taiho Oncology (Inst)
 
John Strickler
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Consulting or Advisory Role - Abbvie; Alterome Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeOne; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Cytovation; Daiichi Sankyo/Astra Zeneca; Exelixis; Full-Life Technologies; GE Healthcare; GlaxoSmithKline; Incyte; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Leap Therapeutics; Lilly; Merck; Merck; Natera (Inst); Pfizer; Pheon Therapeutics; Quanta Therapeutics; Regeneron; Revolution Medicines; Roche/Genentech; Sanofi; Taiho Oncology; Takeda; Xilio Therapeutics; Xilio Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Apollo Therapeutics; AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Daiichi Sankyo/Lilly (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Novartis; Pfizer; Quanta Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst)
Expert Testimony - Seagen
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masafumi Ikeda
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Exact Sciences; Guardant Health; Incyte; MSD; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Delta-Fly Pharma; Eisai; GlaxoSmithKline; Guardant Health; MSD; Nihon Medi-Physics; Novartis; Ono Yakuhin; Rakuten Medical Japan; Roche; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; Biologix FZC; Bristol-Myers Squibb Italy; Eisai; Eisai; Gilead Sciences; Guerbet; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; ArQule; AstraZeneca; Basilea; Baxter; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Eisai; Eisai; Elevar Therapeutics; Exelixis; Genenta Science; Guerbet; Hengrui Therapeutics; Incyte; Ipsen; IQvia; Italfarmaco; Jazz Pharmaceuticals; Lilly; Merck Sharp & Dohme; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Oncology; Zymeworks; Zymeworks
Research Funding - Abbvie (Inst); Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); Jazz Pharmaceuticals; Lilly (Inst); Merck Sharp & Dohme (Inst); Nerviano Medical Sciences (Inst); Roche; SERVIER (Inst); Taiho Oncology (Inst); TransThera Sciences (Nanjing), Inc. (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Ipsen; SERVIER
 
Mitesh Borad
Consulting or Advisory Role - Genentech; Guardant Health; Kriya Therapeutics; Senti Biosciences; Tempus; Zymeworks
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Basilea (Inst); Biond Biologics (Inst); Compass Therapeutics (Inst); Elevar Therapeutics (Inst); Incyte (Inst); Kinnate Biopharma (Inst); Merck Serono (Inst); Nuvectis Pharma (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Seagen (Inst); ZielBio (Inst)
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis